라임병 : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

Lyme Disease Emerging Therapy and TPP Insights

Thelansis's "Lyme Disease Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Lyme Disease Overview

Lyme disease is a tick-borne bacterial infection that, when caught early, is generally treated successfully with a short course of oral antibiotics, making acute care for typical presentations a largely solved clinical problem. The more persistent challenge lies at two edges of that success: a meaningful minority of patients continue to experience fatigue, joint pain, or cognitive symptoms even after standard antibiotic treatment; a poorly understood condition that has resisted consensus diagnosis and effective therapy, and prevention has lacked a viable tool since an earlier vaccine was withdrawn from the market decades ago. That prevention gap now appears close to closing, as a next-generation vaccine candidate has cleared a pivotal late-stage trial and is advancing toward regulatory review, marking what would be the first new Lyme vaccine in a generation. Complementary strategies, including long-acting antibody-based prophylaxis and tick-targeted medications designed to block transmission before infection occurs, are also progressing through earlier development. For stakeholders, Lyme disease shows a category pivoting from acute treatment alone toward genuine prevention.

Key Highlights

• In Germany, incident Lyme disease cases are projected to increase from 56,330 in 2025 to 57,357 by 2035.
• Lyme disease is the most common tick-borne bacterial infection, with early diagnosis being critical to prevent long-term complications.
• Delayed or inadequate treatment may lead to persistent neurological, cardiac, and musculoskeletal manifestations.
• Significant unmet need remains for improved diagnostics and therapies for persistent or difficult-to-treat disease.

Market Overview

• The France Lyme disease market is projected to grow from $70M in 2025 to $160M by 2035.
• Market growth is driven by:
• Increasing disease awareness and improved diagnostic testing
• Ongoing development of novel anti-infective therapies and vaccines
• Future growth will depend on advancements in early diagnosis, preventive strategies, and more effective treatment options.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Pfizer
• ModernaTX, Inc.
• Tarsus Pharmaceuticals, Inc.
• Biocodex

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)